Compare Amphastar Pharmaceuticals Inc (AMPH) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while First Trust NASDAQ 100 Technology Index Fund trades at $315.63. The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | QTEC | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $335.74 |
52-Week Low | $16.87 | $207.03 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
QTEC trades at $316.59, up 1.7% with a bullish technical signal from moving averages. The ETF, tracking NASDAQ-100 technology stocks, lacks disclosed P/E and P/S ratios. A small dividend of $0.03 is scheduled for June 2026, with support at $313 and resistance at $319.
Outlook remains positive due to strong technical momentum, though overbought RSI signals caution. Risks include tech sector volatility and reliance on broad market trends. Analyst coverage highlights its role for diversified tech exposure without specific ratings available.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
